絞り込み

16633

広告

宇宙ビジネス シニア人材をベンチャー企業に!

宇宙ビジネス分野のベンチャー企業に、JAXA=宇宙航空研究開発機構などのシニア人材を引き合わせる取り組みがこの秋から始まります。経済産業省が主導し、日本の宇宙産...

  1. タイ:プラごみ誤飲 ジュゴンの赤ちゃん死...
  2. 優生社会を問う:新型出生前診断 利益大き...
  3. 安定狭心症患者に対する鍼治療のRCT (...
  4. 咳嗽診療、どこから「本気」を出す? (日...

ニュース一覧

「vildagliptin」の検索結果

1017件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Dipeptidyl-peptidase-4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in Systemic Sclerosis.

Risk of Fractures Associated with Dipeptidyl Peptidase-4 Inhibitor Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Prevalence and association of co-morbidities in diabetic patients along with prescription patterns in Delhi-NCT, India.

Design, synthesis and evaluation of DNA nano-cubes as a core material protected by the alginate coating for oral administration of anti-diabetic drug.

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.

Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study.

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

DPP-4 Inhibition and the Path to Clinical Proof.

Pretreatment with vildagliptin boosts ischemic-postconditioning effects on cardioprotection and expression profile of genes regulating autophagy and mitochondrial fission/fusion in diabetic heart with reperfusion injury.

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.

Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.

Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.

Asymmetric Hydrocyanation of Alkenes without HCN.

DPP4 inhibitor induces beta cell regeneration and DDR-1 protein expression as an endocrine progenitor cell marker in neonatal STZ-diabetic rats.

Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment.

Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.

Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.

Placental extracellular vesicles express active dipeptidyl peptidase IV; levels are increased in gestational diabetes mellitus.

A pre-specified statistical analysis plan for the VERIFY study: vildagliptin efficacy in combination with metformin for early treatment of T2DM.

Type 2 diabetic female with vildagliptin associated eczematous eruption.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります